Actinium Pharmaceuticals has initiated a first-in-human Phase 1 study of ATNM-400, a novel HER3-targeted radiotherapy for metastatic castration-resistant prostate cancer (mCRPC). Unlike existing PSMA-targeted treatments, ATNM-400 targets the HER3 antigen, potentially overcoming resistance and benefiting a broader patient group, including those with low or negative PSMA expression. The study uses imaging to guide dosing and patient selection, aiming to establish safety and efficacy. Results presented at ESMO 2026 highlight promising tumor retention and tolerability, supporting further development and potential expansion into other solid tumors.
Actinium Pharmaceuticals' new prostate cancer therapy study is the subject, with Pluang's health sector market data providing context. Of 150 health-sector US stocks priced on Pluang, 42 rose and 97 fell as of Oct 23, 2026 17:41 WIB. Notable movers include Bruker Corporation at USD 56.00 with a -2.29% change and Inovio Pharmaceuticals at USD 0.86 with a +2.09% change.
AX1 has launched Console 2.0, a platform on the Base blockchain that lets AI agents perform tasks and get paid in USDC using the x402 payment standard by Coinbase. This new version simplifies setup, allowing users to deploy AI agents quickly to work ...
The global generator cooling systems market is projected to grow from $3.76 billion in 2026 to $5.03 billion by 2031 at a CAGR of 6.0%. Growth is fueled by rising demand for reliable backup and continuous power in expanding data centers, industrial f...
The global computed tomography (CT) market is undergoing significant innovation driven by photon-counting technology, AI integration, mobile imaging, and point-of-care applications. These advancements are enhancing image quality, workflow efficiency,...
Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...
Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...
